MXCT — MaxCyte Inc

MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ. It is led by Maher Masoud, based in 9713 Key West Avenue, Rockville, MD, United States, 20850, with about 91 employees. MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Latest reported MXCT revenue for 2025-09-30 was $6.8M. Net income was -$35.0M. Revenue was down 19.7% from 2025-06-30 to 2025-09-30. MXCT currently screens at market cap $124.3M.

Use this MXCT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MXCT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MXCT SEC filings page. Lician reads the product cache first so this HTML stays unique to MaxCyte Inc even when a live quote feed is slow.